Stockscreener 앱 받기
1.31
2.24%
-0.03
전일 마감가:
$1.34
열려 있는:
$1.34
하루 거래량:
4.92M
Relative Volume:
0.82
시가총액:
$452.59M
수익:
$22,000
순이익/손실:
$-173.76M
주가수익비율:
-1.7055
EPS:
-0.7681
순현금흐름:
$-109.53M
1주 성능:
-10.27%
1개월 성능:
-22.49%
6개월 성능:
-44.73%
1년 성능:
+3.15%
1일 변동 폭
$1.29
$1.34
1주일 범위
$1.22
$1.46
52주 변동 폭
$1.04
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
명칭
Allogene Therapeutics Inc
전화
(650) 457-2700
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
1.31 | 452.59M | 22,000 | -173.76M | -109.53M | -0.7681 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2026-04-10 | 재개 | Jefferies | Buy |
| 2026-01-09 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-05-14 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | 업그레이드 | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | 재개 | Oppenheimer | Outperform |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 개시 | Citigroup | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-21 | 개시 | Bernstein | Mkt Perform |
| 2023-01-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-01-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2022-08-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-06-03 | 개시 | Robert W. Baird | Neutral |
| 2022-02-28 | 재확인 | B. Riley Securities | Buy |
| 2021-10-20 | 개시 | Cowen | Outperform |
| 2021-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-10-08 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-09-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 재개 | Jefferies | Buy |
| 2021-05-20 | 업그레이드 | Truist | Hold → Buy |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-01-26 | 업그레이드 | Stifel | Hold → Buy |
| 2020-12-10 | 재개 | H.C. Wainwright | Buy |
| 2020-11-24 | 개시 | BofA Securities | Buy |
| 2020-10-23 | 개시 | RBC Capital Mkts | Outperform |
| 2020-06-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-19 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2020-05-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-05-14 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-14 | 다운그레이드 | SunTrust | Buy → Hold |
| 2020-04-13 | 개시 | SunTrust | Buy |
| 2020-03-13 | 개시 | H.C. Wainwright | Buy |
| 2020-03-05 | 개시 | Stifel | Hold |
| 2020-02-24 | 개시 | Berenberg | Hold |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-11-04 | 개시 | Canaccord Genuity | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-05 | 개시 | ROTH Capital | Neutral |
| 2019-05-31 | 개시 | Guggenheim | Neutral |
| 2019-05-23 | 개시 | Stifel | Hold |
| 2019-03-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스
Form 13D/A Allogene Therapeutics For: 1 October By Investing.com - Investing.com Nigeria
TPG Fully Divests Stake in Allogene Therapeutics, Reports Zero Ownership - Kalkine Media
At $1.55 a share, TPG funds sold Allogene Therapeutics (ALLO) stock. - Stock Titan
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Allogene CEO Zach Roberts Is Pushing to Make CAR T-Cell Therapy More Accessible: 'That's What Gets Me Out of Bed' - survivornet.com
Transcript : Allogene Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 08 - marketscreener.com
Allogene at Citi summit: mrD strategy and cash runway in focus - investing.com
Allogene: If MRD Holds, This Becomes A Completely Different Company - Seeking Alpha
Allogene Therapeutics Announces Retirement of Chief Financial Officer - The Globe and Mail
Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Chief Financial Officer, Effective November 6, 2026 - marketscreener.com
Allogene Therapeutics, Inc. Announces Retirement of Geoffrey Parker as Executive Vice President and Principal Financial Officer, Effective November 6, 2026 - marketscreener.com
Allogene Therapeutics CFO Geoffrey Parker Announces Retirement Effective November 2026 - Kalkine Media
Allogene CFO Geoffrey Parker to retire in November By Investing.com - Investing.com Nigeria
Allogene Therapeutics (ALLO) CFO Retirement Highlights Challenges Amid High Price-to-Sales Valuation - GuruFocus
Allogene Therapeutics CFO Geoffrey Parker to Retire - marketscreener.com
Allogene CFO Geoffrey Parker to retire in November By Investing.com - Investing.com South Africa
Allogene CFO Geoffrey Parker to retire in November - Investing.com
Allogene's Geoffrey Parker to Retire as CFO, Effective Nov 6, 2026 - TradingView
Allogene CFO Geoffrey Parker to retire in November By Investing.com - Investing.com UK
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker - globenewswire.com
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker - Yahoo Finance
Allogene Therapeutics CFO Geoffrey Parker to Retire - Yahoo Finance
Allogene Therapeutics Announces Participation in September Investor Conference - GlobeNewswire
Allogene Therapeutics Announces Participation in September Investor Conference - Yahoo Finance
Allogene Therapeutics: Is The Market Looking At CAR-T Persistence The Wrong Way? (ALLO) - Seeking Alpha
Allogene Therapeutics Inc. (ALLO) Key Financial Ratios – Valuation, Profitability & More - Value Research
Allogene (NASDAQ: ALLO) exec share sale is tax ‘sell to cover’ - Stock Titan
Allogene (NASDAQ: ALLO) exec plans sale of 29,697 shares - Stock Titan
Allogene Therapeutics, Inc. SEC Filing (Aug 21, 2026) - Stock Titan
Allogene (ALLO) Earnings Report: The Bottom-Line Figure Outpaces Its Comparison in the Current Update; Stock Move: Shares Finish 5.83% Down in the Available RecordEarnings Season Outlook - Vinanet
Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth - Moomoo
Allogene Therapeutics, Inc. (ALLO) Stock Price, News, Quote & History - Yahoo Finance
Allogene (ALLO) Q2 2026 Earnings Call Transcript - Yahoo Finance
Allogene Therapeutics (ALLO) Institutional Ownership 2026 $ALLO - MarketBeat
Allogene Therapeutics, Inc. (ALLO) Latest Stock News & Headlines - Yahoo Finance
ALLO Reiterated by Citizens -- Price Target Maintained at $6.00 - GuruFocus
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com Nigeria
Citizens reiterates Allogene stock rating on trial progress - Investing.com
Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Allogene stock rating on trial progress By Investing.com - Investing.com India
Citizens reiterates Allogene stock rating on trial progress - Investing.com
Allogene Therapeutics (ALLO) Gains 3.54% as Shares Approach $2.15 ResistanceDemand Zone - vinanet.vn
Walleye Capital LLC Invests $6.80 Million in Allogene Therapeutics, Inc. $ALLO - MarketBeat
Allogene Therapeutics (ALLO): Frazier funds disclose 5.6% ownership and affiliated stakes - Stock Titan
Allogene Therapeutics (ALLO) Income Statement & Earnings - Moomoo
Clinical: FDA Accelerates Allogene's TALEN-Edited Lymphoma Cell Therapy - CRISPR Medicine News
State Street Corp Expands Allogene Therapeutics (ALLO) Stake wit - GuruFocus
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - The Globe and Mail
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs - Yahoo Finance
Allogene Therapeutics Inc (ALLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Allogene Therapeutics Inc 주식 (ALLO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Douglas Earl Martin | Officer |
Aug 21 '26 |
Proposed Sale |
2.12 |
29,697 |
62,958 |
0 |
| Kazam Joshua A | Director |
Jun 18 '26 |
Option Exercise |
0.00 |
47,700 |
0 |
398,463 |
| Yoshiyama Annie | SVP, Finance |
Apr 21 '26 |
Sale |
2.31 |
9,586 |
22,144 |
124,517 |
| Yoshiyama Annie | Officer |
Apr 21 '26 |
Proposed Sale |
2.31 |
9,586 |
22,103 |
0 |
| Beneski Benjamin Machinas | Officer |
Apr 01 '26 |
Proposed Sale |
2.50 |
2,867 |
7,168 |
0 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer |
Mar 31 '26 |
Sale |
2.50 |
2,867 |
7,168 |
195,338 |
| Beneski Benjamin Machinas | SVP, Chief Technical Officer |
Mar 16 '26 |
Sale |
2.47 |
4,835 |
11,942 |
198,205 |
| Chang David D | President and CEO |
Mar 16 '26 |
Sale |
2.47 |
47,763 |
117,975 |
5,150,599 |
| Beneski Benjamin Machinas | Officer |
Mar 16 '26 |
Proposed Sale |
2.47 |
4,835 |
11,928 |
0 |
| Chang David D | Officer |
Mar 16 '26 |
Proposed Sale |
2.47 |
47,763 |
117,827 |
0 |
4.22%
자본화:
|
볼륨(24시간):